Gate2Brain at ACCELERATE 2025: A Decade of Impact and Future Innovations in Pediatric Oncology
On February 6-7, 2025, Gate2Brain had the privilege of participating in the 10th Annual ACCELERATE Conference in Brussels. This significant event brought together a global community of experts, including patient advocates, researchers, regulatory authorities, and industry leaders, all dedicated to advancing pediatric oncology drug development.
Strengthening Collaborations and Insights
Gate2Brain’s Preclinical and Clinical Project Manager, Helena Castillo, represented the company at this gathering. Her participation was instrumental in engaging with key stakeholders and reinforcing Gate2Brain’s commitment to revolutionizing drug delivery for pediatric brain cancer therapies.
Addressing Challenges and Exploring Opportunities
ACCELERATE 2025 provided valuable insights into the evolving landscape of pediatric oncology drug development. Topics such as regulatory challenges, clinical trial design, and innovative therapeutic strategies were at the forefront of discussions. These align closely with Gate2Brain’s mission to enhance drug delivery to the brain using its cutting-edge peptide-shuttle technology. Understanding the latest regulatory requirements and clinical advancements is essential in driving the development of more effective and targeted therapies for children facing brain cancer.
Looking Ahead
As ACCELERATE marks a decade of impact, Gate2Brain remains steadfast in its pursuit of innovative solutions for pediatric brain cancer. The knowledge gained and the connections established during this conference will undoubtedly contribute to future advancements in the field. We extend our gratitude to the entire ACCELERATE community for their dedication and collaboration, shaping the future of pediatric drug development.
Here’s to another decade of progress and breakthroughs in pediatric oncology!
